Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.310 +0.090 (+7.38%)
Streaming Delayed Price Updated: 2:27 PM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,371,206
Open 1.250
Bid (Size) 1.300 (700)
Ask (Size) 1.310 (1,600)
Prev. Close 1.220
Today's Range 1.190 - 1.310
52wk Range 0.8719 - 6.440
Shares Outstanding 35,631,576
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill

Performance

YTD
-64.5%
-64.5%
1 Month
-4.4%
-4.4%
3 Month
-27.6%
-27.6%
6 Month
-50.2%
-50.2%
1 Year
-77.4%
-77.4%

More News

Read More
News headline image
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Jefferies London Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study ↗
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Dow Jumps Over 100 Points; McCormick Earnings Top Views ↗
Via Benzinga
Topics Stocks
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Biomea Fusion Announces Pricing of Public Offering of Securities
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Biomea Fusion Announces Proposed Public Offering of Securities
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
From Biomea Fusion, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Biomea Fusion, Inc. - Common Stock publicly traded?
Yes, Biomea Fusion, Inc. - Common Stock is publicly traded.
What exchange does Biomea Fusion, Inc. - Common Stock trade on?
Biomea Fusion, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Biomea Fusion, Inc. - Common Stock?
The ticker symbol for Biomea Fusion, Inc. - Common Stock is BMEA on the Nasdaq Stock Market
What is the current price of Biomea Fusion, Inc. - Common Stock?
The current price of Biomea Fusion, Inc. - Common Stock is 1.310
When was Biomea Fusion, Inc. - Common Stock last traded?
The last trade of Biomea Fusion, Inc. - Common Stock was at 12/08/25 02:27 PM ET
What is the market capitalization of Biomea Fusion, Inc. - Common Stock?
The market capitalization of Biomea Fusion, Inc. - Common Stock is 46.68M
How many shares of Biomea Fusion, Inc. - Common Stock are outstanding?
Biomea Fusion, Inc. - Common Stock has 47M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.